Filtered By:
Source: PM and R
Condition: Dementia
Education: Study
This page shows you your search results in order of date.
Order by Relevance | Date
Total 2 results found since Jan 2013.
Safety, Tolerability, and Effectiveness of Dextromethorphan/Quinidine for Pseudobulbar Affect Among Study Participants With Traumatic Brain Injury: Results From the PRISM-II Open Label Study
Dextromethorphan 20mg /quinidine 10mg (DM/Q) was approved to treat pseudobulbar affect (PBA) based upon phase 3 trials conducted in participants with amyotrophic lateral sclerosis or multiple sclerosis. PRISM II evaluated DM/Q effectiveness, safety and tolerability for PBA following stroke, dementia or traumatic brain injury (TBI). Objective. To report results from the TBI cohort of PRISM II, including a TBI-specific functional scale. Design. Open-label trial evaluating twice daily DM/Q over 90 days.
Source: PM and R - February 22, 2018 Category: Rehabilitation Authors: Flora M. Hammond, William Sauve, Fred Ledon, Charles Davis, Andrea E. Formella Source Type: research
